The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.
Heidi C WatersRobert StellhornMaëlys TouyaHeather M FitzgeraldSandipan BhattacharjeeCitrome LesliePublished in: Journal of medical economics (2023)
This analysis extends previous evidence for the benefits of AOM in patients with new episodes of schizophrenia, by demonstrating lower HCRU, risk of hospitalization, and healthcare costs with early AOM initiation compared with later initiation.